SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Berger, A. P.,Kofler, K.,Bektic, J.,Rogatsch, H.,Steiner, H.,Bartsch, G., and Klocker, H. ( 2003) Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 57, 5765.
  • 2
    Ghafar, M. A.,Puchner, P. J.,Anastasiadis, A. G.,Cabelin, M. A., and Buttyan, R. ( 2002) Does the prostatic vascular system contribute to the development of benign prostatic hyperplasia? Curr. Urol. Rep. 3, 292296.
  • 3
    Oesterling, J. E. ( 1991) Prostate-specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 45, 907923.
  • 4
    Oesterling, J. E.,Jacobsen, S. J.,Chute, C. G.,Guess, H. A.,Girman, C. J.,Panser, L. A., and Lieber, M. M. ( 1993) Serum prostate-specific antigen in a community-based population of healthy men. J. Am. Med. Assoc. 270, 860864.
  • 5
    Stamey, T. A.,Yang, N.,Hay, A. R.,McNeal, J. E.,Freiha, F. S., and Redwine, E. ( 1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317, 909916.
  • 6
    Roehrborn, C. G.,Picken, C. J., and Carmody, T. ( 1996) Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population. Urology 47, 5966.
  • 7
    Mettlin, C.,Jones, G.,Averette, H.,Gusberg, S. B., and Murphy, G. P. ( 1993) Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J. Clin. 43, 4246.
  • 8
    American Urological Association.( 1992) Early detection of prostate cancer and use of transrectal ultrasound. In American Urological Association 1992 Policy Statement Book. Vol. 4, p. 20, American Urological Association, Baltimore, MD.
  • 9
    Henderson, R. J.,Eastham, J. A.,Culkin, D. J.,Kattan, M. W.,Whatley, T.,Mata, J.,Venable, D., and Sartor, O. ( 1997) Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J. Natl. Cancer Inst. 89, 134138.
  • 10
    Oesterling, J. E. ( 1992) Prostate-specific antigen: improving its ability to diagnose early prostate cancer. J. Am. Med. Assoc. 267, 22362238.
  • 11
    Solomon, K. R. and Freeman, M. R. ( 2008) Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol. Metab. 19, 113121.
  • 12
    Youssef, S.,Stuve, O.,Patarroyo, J. C.,Ruiz, P. J.,Radosevich, J. L.,Hur, E. M.,Bravo, M.,Mitchell, D. J.,Sobel, R. A.,Steinman, L., and Zamvil, S. S. ( 2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420, 7884.
  • 13
    Weis, M.,Heeschen, C.,Glassford, A. J., and Cooke, J. P. ( 2002) Statins have biphasic effects on angiogenesis. Circulation 105, 739745.
  • 14
    Rao, S.,Porter, D. C.,Chen, X.,Herliczek, T.,Lowe, M., and Keyomarsi, K. ( 1999) Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc. Natl. Acad. Sci. 96, 77977802.
  • 15
    Kusama, T.,Mukai, M.,Iwasaki, T.,Tatsuta, M.,Matsumoto, Y.,Akedo, H., and Nakamura, H. ( 2001) Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res. 61, 48854891.
  • 16
    Marcelli, M.,Cunningham, G. R.,Haidacher, S. J.,Padavattv, S. J.,Sturgis, L.,Kagan, C., and Denner, L. ( 2001) Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res. 7, 20672075.
  • 17
    Demierre, M. F.,Higgins, P. D.,Gruber, S. B.,Hawke, E., and Lippman, S. M. ( 2005) Statins and cancer prevention. Nat. Rev. Cancer 5, 930942.
  • 18
    Graaf, M. R.,Richel, D. J.,van Noorden, C. J., and Guchelaar, H. J. ( 2004) Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat. Rev. 30, 609641.
  • 19
    Weber, M. J. and Gioeli, D. ( 2004) Ras signaling in prostate cancer progression. J. Cell. Biochem. 91, 1325.
  • 20
    Hoque, A.,Chen, H., and Xu, X. ( 2008) Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol. Biomarkers Prev. 17, 8894.
  • 21
    Heemers, H.,Maes, B.,Foufelle, F.,Heyns, W.,Verhoeven, G., and Swinnen, J. V. ( 2001) Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol. Endocrinol. 15, 18171828.
  • 22
    Heemers, H.,Vanderhoydonc, F.,Roskams, T.,Schecter, I.,Heyns, W.,Verhoeven, G., and Swinnen, J. V. ( 2003) Androgens stimulate coordinated lipgenic gene expression in normal target tissues in vivo. Mol. Cell. Endocrinol. 205, 2131.
  • 23
    Swinnen, J. V.,Heemers, H.,van de Sande, T.,de Schrijver, E.,Brusselmans, K.,Heyns, W., and Verhoeven, G. ( 2004) Androgens, lipogenesis and prostate cancer. J Steroid Biochem. Mol. Biol. 92, 273279.
  • 24
    Eberle, D.,Hegarty, B.,Bossard, P.,Ferre, P., and Foufelle F. ( 2004) SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 86, 839848.
  • 25
    Freeman, M. R. and Solomon, K. R. ( 2004) Cholesterol and prostate cancer. J. Cell Biochem. 91, 5469.
  • 26
    Simons, K. and Ikonen, E. ( 1997) Functional rafts in cell membranes. Nature 387, 569572.
  • 27
    Manes, S.,Mira, E.,Gomez-Mouton, C.,Lacalle, R. A.,Keller, P.,Labrador, J. P., and Martinez, A. C. ( 1999) Membrane raft microdomains mediate front-rear polarity in migrating cells. J. Eur. Mol. Biol. Org. 18, 62116220.
  • 28
    Hager, M. H.,Solomon, K. R., and Freeman, M. R. ( 2006) The role of cholesterol in prostate cancer. Curr. Opin. Clin. Nutr. Metab. 9, 379385.
  • 29
    Freeman, M. R.,Cinar, B., and Lu, M. L. ( 2005) Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol. Metab. 16, 273279.
  • 30
    Zhuang, L.,Lin, J.,Lu, M. L.,Solomon, K. R., and Freeman, M. R. ( 2002) Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res. 62, 22272231.
  • 31
    Smith, S. M.,Lei, Y.,Liu, J.,Cahill, M. E.,Hagen, G. M.,Barisas, B. G., and Roess, D. A. ( 2006) Luteinizing hormone receptors translocate to plasma membrane microdomains after binding of human chorionic gonadotropin. Endocrinology 147, 17891795.
  • 32
    Porstmann, T.,Griffiths, B.,Chung, Y. L.,Delpuech, O.,Griffiths, J. R.,Downward, J., and Shulze, A. ( 2005) PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24, 64656481.
  • 33
    Skaletz-Rorowski, A.,Lutchman, M.,Kureishi, Y.,Lefer, D. J., and Faust, J. R. ( 2003) HMG-CoA reductase inhibitors promote cholesterol-dependent Akt/PKB translocation to membrane domains in endothelial cells. Cardiovasc. Res. 57, 253264.
  • 34
    Ettinger, S. L.,Sobel, R.,Whitmore, T. G.,Akbari, M.,Bradley, D. R.,Gleave, M. E., and Nelson, C. C. ( 2004) Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res. 64, 22122221.
  • 35
    El Sheikh, S. S.,Domin, J.,Abel, P.,Stamp, G., and Lalani el, N. ( 2004) Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia 6, 846853.
  • 36
    Skaletz-Rorowski, A. and Walsh, K. ( 2003) Statin therapy and angiogenesis. Curr. Opin. Lipidol. 14, 599603.
  • 37
    Faust, J. R.,Brown, M. S., and Goldstein, J. L. ( 1980) Synthesis of delta 2-isopentenyl tRNA from mevalonate in cultured human fibroblasts. J. Biol. Chem. 255, 65466548.
  • 38
    Zhuang, L.,Kim, J.,Adam, R. M.,Solomon, K. R., and Freeman, M. R. ( 2005) Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J. Clin. Invest. 115, 959968.
  • 39
    Kureishi, Y.,Luo, Z.,Shiojima, I.,Bialik, A.,Fulton, D.,Lefer, D. J.,Sessa, W. C., and Walsh, K. ( 2000) HMG-CoA reductase inhibitor simvastatin activate the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6, 10041010.
  • 40
    Hall, S. A.,Page, S. T.,Travison, T. G.,Montgomery, R. B.,Link, C. L., and McKinlay, J. B. ( 2007) Do statins affect androgen? Results from the boston area community health survey. Cancer Epidemiol. Biomarkers Prev. 16, 15871594.
  • 41
    Horinaga, M.,Okita, H.,Nakashima, J.,Kanao, K.,Sakamoto, M., and Murai, M. ( 2005) Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer. Urology 66, 671675.
  • 42
    Hamilton, R. J. and Freedland, S. J. ( 2008) Rationale for statins in chemoprevention of prostate cancer. Curr. Urol. Rep. 9, 189196.
  • 43
    Schaffner, G. P. ( 1983) Effect of cholesterol-lowering agents. In Benign Prostatic Hypertrophy. ( Hinman, F.,Jr., ed.). pp. 280, Springer-Verlag, New York.
  • 44
    Loeb, S.,Kan, D.,Helfand, B. T.,Nadler, R. B., and Catalona, W. J. Is statin use associated with prostate cancer aggressiveness? Br. J. Urol. Intl. 105, 12221225.
  • 45
    Lamb, E. ( 2007) Top 200 prescription drugs of 2008. Pharmacy Times. Available at: http://www.pharmacytimes.com/issue/pharmacy/2009/2009-05/RxFocusTop200Drugs-0509. Accessed on February 2010.
  • 46
    Chan, K. K.,Oza, A. M., and Siu, L. L. ( 2003) The statins as anticancer agents. Clin. Cancer Res. 9, 1019.
  • 47
    Stamm, J. A. and Ornstein, D. L. ( 2005) The role of statins in cancer prevention and treatment. Oncology 19, 739750.
  • 48
    Andrews, T. C.,Ballantyne, C. M.,Hsia, J. A., and Kramer, J. H. ( 2001) Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins. Am. J. Med. 111, 185191.
  • 49
    Schaefer, E. J.,McNamara, J. R.,Taler, T.,Daly, J. A.,Gleason, J. L.,Seman, L. J.,Ferrari, A., and Rubenstein, J. J. ( 2004) Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am. J. Cardiol. 93, 3139.
  • 50
    Wong, W. W.,Tan, M. M.,Xia, Z.,Dimitroulakos, J.,Minden, M. D., and Penn, L. Z. ( 2001) Cerivastatin triggers tumor specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res. 7, 20672075.
  • 51
    Negre-Aminou, P.,van Vliet, A. K.,van Erck, M.,van Thiel, G. C.,van Leeuwen, R. E., and Cohen, L. H. ( 1997) Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: comparison with other human cell types. Biochim. Biophys. Acta 1345, 259268.
  • 52
    Boucher, K.,Siegel, C. S.,Sharma, P.,Hauschka, P. V., and Solomon, K. R. ( 2006) HMG-CoA reductase inhibitors induce apoptosis in pericytes. Microvasc. Res. 71, 91102.
  • 53
    Hengst, L.,Dulic, V.,Slingerland, J. M.,Lees, E., and Reed, S. I. ( 1994) A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc. Natl. Acad. Sci. USA 91, 52915295.
  • 54
    Hengst, L. and Reed, S. I. ( 1996) Translational control of p27kip1 accumulation during the cell cycle. Science (Washington, DC) 271, 18611864.
  • 55
    Cyrus-David, M. S.,Weinberg, A.,Thompson, T., and Kadmon, D. ( 2005) The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J. Urol. 173, 19231925.
  • 56
    Moyad, M. A.,Merrick, G. S.,Butler, W. M.,Wallner, K. E.,Galbreath, R. W.,Kurko, B., and Adamovich, E. ( 2005) Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. J. Urol. 66, 11501154.
  • 57
    Soto, D. E.,Daignault, S.,Sandler, H. M., and Ray, M. E. ( 2009) No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology 73, 158162.
  • 58
    Katz, M. O.,Zelefsky, M. J., and Marion, C. ( 2003) Statin use is associated with improved biochemical outcome after high dose radiotherapy for clinically localized prostate cancer (abstract). Intl. J. Radiat. Oncol. Biol. Phys. 57( 2 Suppl. 1), S271.
  • 59
    Mills, I. W.,Crossland, A.,Patel, A., and Ramonas, H. ( 2007) Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement. Eur. Urol. 52, 503509.
  • 60
    Hamilton, R. J.,Goldberg, K. C.,Platz, E. A., and Freedland, S. J. ( 2008) The influence of statin medications on prostate-specific antigen levels. J. Natl. Cancer Inst. 100, 15111518.
  • 61
    Stamatiou, K. N.,Zaglavira, P.,Skolarikos, A., and Sofras, F. ( 2008) The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride. Clin. Urol. 34, 555562.
  • 62
    Mener, D. J.,Cambio, A.,Stoddard, D. G.,Martin, B. A., and Palapattu, G. S. The impact of HMG-CoA reductase therapy on serum PSA. Prostate, 70, 608615.
  • 63
    Thibault, A.,Samid, D.,Tompkins, A. C.,Figg, W. D.,Cooper, M. R.,Hohl, R. J.,Trepel, J.,Liang, B.,Patronas, N.,Venzon, D. J.,Reed, E., and Myers, C. E. ( 1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway in patients with cancer. Clin. Cancer Res. 2, 483491.
  • 64
    Urbich, C.,Dernbach, E.,Zeiher, A. M., and Dimmeler, S. ( 2002) Double edged role of statins in angiogenesis signaling. Circ. Res. 90, 737744.
  • 65
    Krane, S. L.,Kaul, S. A.,Stricker, H. J.,Peabody, J. O.,Menon, M., and Agarwal, P. K. ( 2010) Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen. J. Urol. 183, 118125.
  • 66
    Murtola, T. J.,Tammela, T.,Maattanen, L.,Huhtala, H.,Platz, E. A.,Ala-Opas, M.,Stenman, U., and Auvinen, A. Prostate cancer and PSA among statin users in the finnish prostate cancer screening trial. Intl. J. Cancer, DOI: 10.1002/ijc.25165.